Xenon Pharmaceuticals - XENE Stock Forecast, Price & News

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Xenon Pharmaceuticals Trading Up 3.1 %

Shares of NASDAQ:XENE traded up $1.18 on Monday, hitting $39.65. The company had a trading volume of 715,976 shares, compared to its average volume of 485,006. Xenon Pharmaceuticals has a 1-year low of $14.65 and a 1-year high of $40.34. The stock has a market cap of $2.11 billion, a price-to-earnings ratio of -22.15 and a beta of 1.53. The stock has a 50 day moving average price of $31.69 and a 200 day moving average price of $30.73.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Rating) last released its quarterly earnings data on Tuesday, May 10th. The biopharmaceutical company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.03. Xenon Pharmaceuticals had a negative net margin of 360.80% and a negative return on equity of 20.94%. The firm had revenue of $8.77 million for the quarter, compared to the consensus estimate of $9.22 million. During the same period in the previous year, the company earned ($0.42) earnings per share. Sell-side analysts anticipate that Xenon Pharmaceuticals will post -2.07 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on XENE shares. StockNews.com upgraded shares of Xenon Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Wednesday, July 27th. JPMorgan Chase & Co. assumed coverage on shares of Xenon Pharmaceuticals in a report on Thursday, July 21st. They set an "overweight" rating and a $55.00 target price on the stock. Finally, Wedbush lowered their target price on shares of Xenon Pharmaceuticals from $47.00 to $41.00 and set an "outperform" rating on the stock in a report on Monday, June 27th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $45.33.